What is VCYT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 3.64B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for VCYT?

P/E (TTM) is 31.76 and 52-week range is $29.45 to $60.91 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s VCYT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for VCYT?

The company profile lists revenue (TTM) near $546M, net income (TTM) near $111M, EPS (TTM) near $1.40 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Veracyte Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in South San Francisco, California, US, 79.8M shares outstanding, ISIN US92337F1075 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Veracyte Inc

$VCYT

Health Care · Biotechnology

IR Run Scenarios

$45.23

+3.74%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The company is headquartered in South San Francisco, California and currently employs 755 full-time employees. The company went IPO on 2013-10-30. The firm enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The firm offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). The company has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.

Employees

755

Website

www.veracyte.com/

IPO

2013-10-30

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)